Reuters logo
BRIEF-Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals
January 9, 2017 / 1:11 AM / a year ago

BRIEF-Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals

Jan 8 (Reuters) - Ipsen Sa

* Ipsen to acquire Oncology Assets from Merrimack Pharmaceuticals

* Entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its product ONIVYDE

* Co to pay $575 million cash at closing plus upto $450 million upon approval of potential additional indications for ONIVYDE in the U.S.

* Deal should be dilutive in 2017 and accretive from 2018 onwards both in operating margin and EPS

* Transaction will be fully financed by Ipsen’s existing cash and lines of credit Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below